


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound according to Formula I, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt of a prodrug thereof



Formula I

wherein R1, R3, R4, R5 and R10 independently are selected from the group consisting of H, halogen, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, OH, CN, O(1-4C)alkyl, S(O)<sub>m</sub>(1-4C)alkyl, optionally substituted with one or more halogen atoms, C(O)(1-4C)alkyl, OC(O)(1-4C)alkyl and NR<sub>19</sub>R<sub>20</sub>,

R2 is selected from the group consisting of H, halogen, NO<sub>2</sub>, NR<sub>11</sub>R<sub>12</sub>, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, OH, O(1-4C)alkyl, S(1-4C)alkyl and OC(O)(1-4C)alkyl,

R6 is selected from the group consisting of H, C(Y)R<sub>15</sub>, C(O)OR<sub>16</sub>, C(S)NR<sub>17</sub>, (1-6C)alkyl, (1-6C)alkoxy-substituted (1-4C)alkyl and (CH<sub>2</sub>)<sub>n</sub>C(O)OR<sub>21</sub>,

R7 is H or R7 is selected from the group consisting of (1-4C)alkyl, (2-4C)alkenyl and (2-4C)alkynyl, all optionally substituted with one or more halogen atoms,

R8 and R9 independently are selected from the group consisting of H and (1-4C)alkyl,

R11 and R12 independently are selected from the group consisting of H, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-6C)alkoxycarbonyl, (1-4C)alkylsulfonyl, and (6-10C)arylsulfonyl,

R15 is H or R15 is selected from the group consisting of (1-6C)alkyl, (3-6C)cycloalkyl, (2-4C)alkenyl or (2-4C)alkynyl, (6-10C)aryl, 1,4-bisaryl, amino(1-4C)alkyl, hydroxy(1-4C)alkyl, and carboxy(1-4C)alkyl, all optionally substituted with one or more halogen atoms,

R16 is (1-6C)alkyl, optionally substituted with one or more halogen atoms,

R17 is selected from the group consisting of (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl and (3-6C)cycloalkyl, all optionally substituted with one or more halogen atoms,

X is ~~selected from the group consisting of O, S, CH<sub>2</sub> and NR~~18,

Y is selected from the group consisting of O, S, and NH,

R18 is selected from the group consisting of H and (1-4C)alkyl,

R19 is selected from the group consisting of H and (1-4C)alkyl,

R20 is selected from the group consisting of H, (1-4C)alkyl, CH<sub>2</sub>(6-10C)aryl, C(O)(1-6C)alkyl and C(O)NH(1-4C)alkyl,

R21 is selected from the group consisting of H and (1-6C)alkyl,

m is 0, 1 or 2, and

n is 1, 2 or 3,

provided that (i) when X is O, R1-R5 are H, R8-R10 are H[.], and R6 is ethyl or C(O)CH<sub>3</sub> then R7 is not H;

(ii) when X is O, R1-R5 are H, R8-R10 are H, and R6 is methyl then R7 is not methyl; and

(iii) when X is O, R1-R5 are H[.], R8-R10 are H, and R6 is H then R7 is not H or ethyl or (CO)CH<sub>3</sub>.

2. (Previously Presented) The compound according to claim 1, wherein R2 is selected from the group consisting of H, halogen, NO<sub>2</sub>, and NR<sub>11</sub>R<sub>12</sub>; and

R<sub>11</sub> and R<sub>12</sub> independently are selected from the group consisting of H, (1-6C)alkoxycarbonyl, (1-4C)alkylsulfonyl and (6-10C)arylsulfonyl.

3. (Previously Presented) The compound according to claim 1, wherein R1 and R5 are H and R3 and R4 are selected from H or halogen.

4. (Previously Presented) The compound according to claim 1, wherein X is selected from the group consisting of O, S and CH<sub>2</sub>.

5. (Previously Presented) The compound according to claim 1, wherein R6 is selected from H or C(Y)R<sub>15</sub> and R<sub>15</sub> is (1-4C)alkyl optionally substituted with one or more halogen atoms or H.

6. (Previously Presented) The compound according to claim 1, wherein

X is O or CH<sub>2</sub>,

R<sub>2</sub> is selected from the group consisting of H, halogen and NO<sub>2</sub> and

R<sub>15</sub> is (1-2C)alkyl optionally substituted with one or more halogen atoms.

7. (Previously Presented) The compounds according to claim 1, wherein

R<sub>11</sub> is H and

R<sub>12</sub> is selected from the group consisting of (1-6C)alkoxycarbonyl, (1-4C) alkylsulfonyl and (6-10C)arylsulfonyl.

8. (Previously Presented) The compound according to claim 1, wherein

R<sub>2</sub> is H,

R<sub>3</sub> is halogen,

R<sub>15</sub> is methyl, optionally substituted with 1-3 halogen atoms and

Y is O or S.

9. (Previously Presented) The compound according to claim 1, wherein R<sub>4</sub> is H and X is O.

10. (Previously Presented) The compound according to claim 1, wherein R<sub>2</sub> is H or halogen,

R<sub>3</sub> and/or R<sub>4</sub> are independently selected from the group consisting of H, ON, halogen, (2-4C)alkenyl and C(O)(1-4C)alkyl, and

R<sub>5</sub> and/or R<sub>10</sub> are independently selected from H or halogen.

11. (Previously Presented) The compound according to claim 1, wherein X is selected from the group consisting of O, S and NCH<sub>3</sub>.

12. (Previously Presented) The compound according to claim 1, wherein R8 and R9 are H.

13. (Currently Amended) The compound according to claim + 10, wherein R6 is H or C(Y)R15 and  
R15 is (1-4C)alkyl, optionally substituted with one or more halogen atoms, or H.

14. (Currently Amended) The compound according to claim + 13, wherein Y is O or S, and  
R15 is methyl, optionally substituted with one or more halogen atoms.

15. (Canceled).

16. (Previously Presented) A pharmaceutical composition, comprising:  
the compound according to claim 1 and  
pharmaceutically acceptable auxiliaries.